Article
Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, two-period crossover study in healthy subjects.
Clinical drug investigation - 1 Jan 2011
Yin Ophelia Q P, Gallagher Neil, Fischer Deirdre, Zhao Lily, Zhou Wei, Leroy Elisabeth, Golor Georg, Schran Horst
Abstract excerpt
BACKGROUND AND OBJECTIVE: Nilotinib (Tasigna®), a highly selective and potent BCR-ABL tyrosine kinase inhibitor, is approved for the treatment of chronic myeloid leukaemia in the chronic phase (CML-CP) and the accelerated phase (CML-AP) in patients resistant or intolerant to prior therapy, including imatinib. Nilotinib has shown competitive inhibition of cytochrome P450 enzyme (CYP) 2C9 in vitro, but its effect...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
